Lebedeva, A V, Shchukin, I A, Soldatov, M A et al. · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · 2014
This study looked at 35 people with multiple sclerosis (MS) who experienced severe fatigue and mood problems. Researchers gave them a supplement called idebenon for 6 months and found it reduced their fatigue, tiredness, and depression. While this is interesting, it's important to note this study focused on MS patients, not ME/CFS patients, though both conditions involve fatigue.
While this study examined MS rather than ME/CFS, understanding how mitochondrial support agents like idebenon affect fatigue and mood in neurological conditions is relevant to ME/CFS research, since some evidence suggests mitochondrial dysfunction may contribute to ME/CFS pathology. The findings on idebenon's tolerability and dosing may inform future ME/CFS intervention research.
This study does not prove that idebenon is effective for ME/CFS patients, as it examined only MS patients. The absence of a placebo control group means improvements could reflect placebo effect, natural disease course, or regression to the mean rather than true drug efficacy. The open-label design and lack of randomization prevent causal conclusions about idebenon's mechanism.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →